Steven Cohen’s Adamas Pharmaceuticals ADMS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-1,150,000
| Closed | -$5.65M | – | 1409 |
|
|
2021
Q3 | $5.65M | Sell |
1,150,000
-1,101,255
| -49% | -$5.35M | 0.02% | 635 |
|
|
2021
Q2 | $11.9M | Buy |
+2,251,255
| New | +$11.7M | 0.05% | 409 |
|
|
2019
Q2 | – | Sell |
-1,050,000
| Closed | -$7.47M | – | 1626 |
|
|
2019
Q1 | $7.47M | Sell |
1,050,000
-1,516,386
| -59% | -$13.6M | 0.03% | 470 |
|
|
2018
Q4 | $21.9M | Buy |
2,566,386
+122,686
| +5% | +$1.6M | 0.11% | 243 |
|
|
2018
Q3 | $48.9M | Buy |
2,443,700
+171,585
| +8% | +$4.03M | 0.2% | 137 |
|
|
2018
Q2 | $58.7M | Buy |
2,272,115
+235,515
| +12% | +$6.52M | 0.23% | 123 |
|
|
2018
Q1 | $48.7M | Sell |
2,036,600
-72,855
| -3% | -$2.3M | 0.2% | 137 |
|
|
2017
Q4 | $71.5M | Buy |
2,109,455
+1,259,290
| +148% | +$35.2M | 0.31% | 83 |
|
|
2017
Q3 | $18M | Buy |
850,165
+735,165
| +639% | +$13.5M | 0.08% | 281 |
|
|
2017
Q2 | $2.01M | Buy |
115,000
+62,700
| +120% | +$1.04M | 0.01% | 649 |
|
|
2017
Q1 | $915K | Sell |
52,300
-112,150
| -68% | -$1.91M | 0.01% | 746 |
|
|
2016
Q4 | $2.78M | Buy |
164,450
+33,950
| +26% | +$525K | 0.02% | 521 |
|
|
2016
Q3 | $2.14M | Sell |
130,500
-13,200
| -9% | -$201K | 0.02% | 557 |
|
|
2016
Q2 | $2.18M | Buy |
+143,700
| New | +$2.37M | 0.01% | 550 |
|
|
2015
Q3 | – | Sell |
-27,000
| Closed | -$708K | – | 941 |
|
|
2015
Q2 | $708K | Buy |
+27,000
| New | +$525K | ﹤0.01% | 626 |
|
Steven Cohen's ADMS Position: Q4 2021 in Review
Steven Cohen sold out of Adamas Pharmaceuticals (ADMS) in Q4 2021, closing a stake of 1,150,000 shares — an estimated $5.65M sold.
Steven Cohen first reported a position in ADMS in Q2 2015 and held it in 15 quarters. The position peaked at $71.5M in Q4 2017. 0 funds tracked by Wall St. Rank hold ADMS as of Q4 2021.
- Steven Cohen reported no remaining Adamas Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
- Steven Cohen sold 1,150,000 Adamas Pharmaceuticals shares in Q4 2021, an estimated $5.65M.
- Steven Cohen first reported a position in Adamas Pharmaceuticals in Q2 2015 and held it in 15 quarters.
- Steven Cohen's Adamas Pharmaceuticals position peaked at $71.5M in Q4 2017.
- 0 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2021.
Based on Point72 Asset Management's 13F filing for Q4 2021, filed 14 Feb 2022.